Treatment of childhood asthma - Options and rationale for inhaled therapy

被引:15
|
作者
Powell, CVE [1 ]
Everard, ML [1 ]
机构
[1] Sheffield Childrens Hosp, Dept Resp Paediat, Sheffield, S Yorkshire, England
关键词
D O I
10.2165/00003495-199855020-00005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Epidemiological studies suggest the prevalence of asthma is increasing, though some remain sceptical as to the magnitude or indeed the presence of an increase, However, despite improved diagnosis and the availability of the potent drugs now available, there remains considerable respiratory morbidity associated with asthma. It is clear from a number of studies that failure to deliver drugs to the lungs when using inhaler devices is a factor contributing to this high level of morbidity, Failure of drug delivery may result from the prescribing of inappropriate devices, failure to use devices appropriately or failure to comply with a treatment regimen. For most of the currently available forms of asthma therapy there are significant advantages to be gained from administering them in aerosol form. The-benefits to be derived from administering these drugs as an aerosol include a rapid onset of action fur drugs such as beta-agonists and a low incidence of systemic effects from drugs such as beta-agonists and corticosteroids. Over the past 25 years our understanding of the nature of asthma has changed. Though this has been reflected in the emphasis on inhaled corticosteroid therapy in recent guidelines, it has not been reflected in the range of inhaler devices available. Manufacturers continue to place drugs such as corticosteroids in the same devices as short actine beta-agonists even though the requirements for these different drug classes are very different. It is likely that this contributes to suboptimal therapeutic responses with inhaled corticosteroids. However, the variability associated with current, delivery systems is relatively small compared with the variability introduced by poor compliance. There is no work currently available to indicate how the use of cheap disposable devises which do not incorporate any form of positive feedback influence compliance with inhaled steroids. Optimising aerosolised drug delivery in childhood involves consideration of the class of drugs, the particular drug within a class but more importantly, the age and abilities of the child. Devices must be selected to suit a particular child's needs and abilities. Devices utilising tidal breathing are generally used such as spacing chambers or, less commonly these days, nebulisers. A screaming or struggling child, or failure to use a closely fitting mask, reduces drug delivery to the lungs enormously. Failure to respond to inhaled therapy in early childhood may be attributable to failure of drug delivery. Drug delivery in early childhood using current devices remains more an art than a science.
引用
收藏
页码:237 / 252
页数:16
相关论文
共 50 条
  • [31] Add-on therapy options in asthma not adequately controlled by inhaled corticosteroids: a comprehensive review
    Hannu Kankaanranta
    Aarne Lahdensuo
    Eeva Moilanen
    Peter J Barnes
    Respiratory Research, 5
  • [32] Inhaled disodium cromoglycate as maintenance therapy for childhood asthma: time to consign to history?
    Helms, PJ
    THORAX, 2000, 55 (11) : 886 - 886
  • [33] Pharmacogenomic Response of Inhaled Corticosteroids for the Treatment of Asthma: Considerations for Therapy
    Cazzola, Mario
    Rogliani, Paola
    Calzetta, Luigino
    Matera, Maria Gabriella
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2020, 13 : 261 - 271
  • [34] Inhaled corticosteroids for asthma therapy
    Kanter, L
    WESTERN JOURNAL OF MEDICINE, 1997, 167 (05): : 348 - 349
  • [35] COMPARISON OF INHALED METAPROTERENOL, ATROPINE, OR A COMBINATION OF BOTH IN TREATMENT OF ACUTE ASTHMA IN CHILDHOOD
    MALONEY, MJ
    GUILL, MF
    CLINICAL RESEARCH, 1984, 32 (05): : A877 - A877
  • [36] Asthma control with montelukast or salmeterol as add-on therapy to inhaled corticosteroid treatment of asthma
    Anstatt, D
    Allen-Ramey, FC
    Korelitz, J
    Bethel, J
    Sajjan, S
    Markson, L
    CHEST, 2003, 124 (04) : 94S - 94S
  • [37] CAN SERUM ECP PREDICT THE NEED FOR TREATMENT WITH INHALED STEROID IN CHILDHOOD ASTHMA
    ZIMMERMAN, B
    LEE, K
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1994, 93 (01) : 185 - 185
  • [38] Where next for inhaled corticosteroids in childhood asthma?
    Sinha, Ian P.
    Dodd, Susanna R.
    Grime, Christopher
    Hawcutt, Daniel B.
    Fernandes, Ricardo M.
    Roberts, Matthew R.
    Simba, Justus M.
    Williamson, Paula R.
    LANCET RESPIRATORY MEDICINE, 2020, 8 (04): : 345 - 345
  • [39] Successful withdrawal of inhaled corticosteroids in childhood asthma
    Jayasiri, B
    Perera, C
    RESPIROLOGY, 2005, 10 (03) : 385 - 388
  • [40] Safety of the Newer Inhaled Corticosteroids in Childhood Asthma
    Tabitha L. Randell
    Kim C. Donaghue
    Geoffrey R. Ambler
    Christopher T. Cowell
    Dominic A. Fitzgerald
    Peter P. Van Asperen
    Pediatric Drugs, 2003, 5 (7) : 481 - 504